Maximizing the Value of New Products To derive the greatest value from new products, we are focusing on maximizing the overactive bladder (OAB)  franchise; building a business base in the field of oncology; launching new products on an ongoing basis  worldwide; and reinforcing our sales operations in emerging markets. Vesicare is one of the leading branded prescription drugs  on the market for OAB treatments. We have also begun  the global introduction of mirabegron (generic name),  which provides a new therapeutic option in OAB as the  result of its different mechanism of action to Vesicare.  Mirabegron is now available in over 25 countries around  the world. Going forward, while focusing even more on  achieving market penetration with mirabegron, we will  maximize the OAB franchise. We are working to establish oncology as our third GCL  area next to urology and transplantation. We are building  up our business base in this field in various regions, and  steadily starting up our operations with the prostate  cancer treatment XTANDI as the key driver of growth.  XTANDI is sold in over 25 countries worldwide. Currently  we are conducting clinical trials in earlier stages of prostate  cancer than current indication and breast cancer. Looking  ahead, we plan to launch XTANDI in more countries, while  also seeking to expand the range of indications for the  drug to maximize its value. The Oncology Field as a Future Growth Driver Maximizing the OAB Franchise continuous product introductions (Approvals and launches from April 2013 to July 2014) Astellas Pharma Inc.  _ Annual Report 2014 24 Asia & Oceania EMEA Japan The Americas Launched • XTANDI (Canada, Argentina) • Myrbetriq (Canada) • ASTAGRAF XL (U.S.) • Tarceva (U.S.) • MYCAMINE (U.S.) • MYCAMINE (Hong Kong) • Prograf XL/Advagraf (Indonesia, the Philippines) • MYCAMINE (Australia, Malaysia, Singapore) • BETMIGA (Hong Kong, South Korea, Taiwan, Australia) • XTANDI (South Korea, Australia) Approved/Launched • Eligard (Hong Kong, Thailand, Vietnam, Singapore, Taiwan,  Malaysia) New indications New indications Approved/Launched Approved/Launched • XTANDI • VESOMNI New indications • Micamlo BP • Irribow OD Tablet •Acofide • Suglat • Bisono Tape • XTANDI • Prograf • Dormicum